Lucosky Brookman LLP is proud to announce its role as Special NASDAQ Counsel to Lucy Scientific Discovery, Inc. in connection with the successful completion of the company’s recent initial public offering (IPO). Lucy Scientific Discovery is a clinical-stage biotechnology company committed to developing innovative gene therapies. The company offered 7,500,000 shares of common stock at a public offering price of $10.00 per share, raising gross proceeds of $75 million before underwriting discounts, commissions, and other expenses. The offering closed on February 13, 2023, and the underwriters have a 45-day option to purchase up to an additional 1,125,000 shares of common stock from Lucy Scientific Discovery.
